On October 31, 2023, Aqtual, a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology, announced it has completed a $16 million Series A round of financing co-led by Genoa Ventures, Manta Ray Ventures, and Yu Galaxy. Wilson Sonsini Goodrich & Rosati advised Aqtual on the transaction.

Aqtual's proprietary platform evaluates protein regulation, epigenetics, and transcriptomics solely using cell-free DNA fragments found in blood. The platform yields efficient and robust real-time analysis of disease and treatment while overcoming the limitations of previous cell-free DNA methodologies.

The Wilson Sonsini team representing Aqtual in the transaction was led by Mark Solakian, Amanda Creedon, and Erica Wolfe Heinz.

For more information, please see Aqtual’s news release.